REGENERON PHARMACEUTICALS, INC.
REGN · XNASCIK 872589fmd_0706GFJPK8BYWG25ZEPRBSGD97Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 71 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4,860 | 5,872 | 5,146 | 6,558 | 8,497 | 16,072 | 12,173 | 13,117 | 14,202 | 14,343 |
| Cost of revenue | 195 | 203 | 238 | 403 | – | – | – | – | – | – |
| Gross profit | 4,666 | 5,670 | 4,908 | 6,155 | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | – | – | – | – |
| Research and development | 2,052 | 2,075 | 1,469 | 2,450 | 2,647 | 2,860 | 3,593 | 4,439 | 5,132 | 5,850 |
| Selling, general and administrative | 1,178 | 1,320 | 1,127 | 1,342 | 1,346 | 1,825 | 2,116 | 2,631 | 2,954 | 2,700 |
| Operating income | 1,331 | 2,080 | 2,534 | 2,210 | 3,577 | 8,947 | 4,739 | 4,047 | 3,991 | 3,578 |
| Interest expense | 7 | 25 | 28 | 30 | 57 | 57 | 59 | 73 | 55 | 44 |
| Other non-operating income (expense) | (1) | (1) | 19 | 219 | 234 | 379 | 120 | 152 | 789 | 1,653 |
| Income before taxes | 1,330 | 2,079 | 2,554 | 2,429 | 3,810 | 9,326 | 4,859 | 4,199 | 4,780 | 5,231 |
| Income tax expense | 434 | 880 | 109 | 313 | 297 | 1,251 | 520 | 246 | 367 | 726 |
| Net income from continuing operations | 896 | 1,199 | 2,444 | 2,116 | 3,513 | 8,075 | 4,338 | 3,954 | 4,413 | 4,505 |
| Net income | 896 | 1,199 | 2,444 | 2,116 | 3,513 | 8,075 | 4,338 | 3,954 | 4,413 | 4,505 |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |